1-methyl-1H-pyrazole-3-sulfonic acid (1-acetyl-2,3-dihydro-1H-indol-6-yl)-(4-chloro-benzyl)-amide | 1257583-08-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-methyl-1H-pyrazole-3-sulfonic acid (1-acetyl-2,3-dihydro-1H-indol-6-yl)-(4-chloro-benzyl)-amide
• 英文别名: N-(1-acetyl-2,3-dihydroindol-6-yl)-N-[(4-chlorophenyl)methyl]-1-methylpyrazole-3-sulfonamide
• CAS: 1257583-08-6
• 化学式: C₂₁H₂₁ClN₄O₃S
• 分子量: 444.942
• InChiKey: KTZLWCMNXPHJHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  83.9
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Compounds
  申请人：Hamlyn Richard John

  公开号：US20110136860A1

  公开（公告）日：2011-06-09

  A compound of formula (I): Or its salts or pharmaceutically acceptable derivatives thereof wherein: A represents a chemical moiety with the general formula (II): X and Y are independently selected from a group consisting of CH 2 , CH(R 5 ) or C(R 5 )(R 6 ); R 1 is selected from the group consisting of optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; R 2 is selected from the group consisting of optionally substituted aryl or optionally substituted heteroaryl or NR 7 R 8 ; R 3 R 4 R 5 R 6 R 7 and R 8 are as defined herein, n=0, 1, 2 or 3; o=0, 1 or 2, with the proviso that when o=0, then n is 1, 2 or 3 and when o=1, then n is 1 or 2 is provided. Pharmaceutical compositions comprising the compounds are also provided. These compounds are useful in the treatment of various disorders including arrhythmia.

  化合物的化学式(I)：或其盐或药学上可接受的衍生物，其中：A代表具有通式(II)的化学基团：X和Y分别选自CH2、CH(R5)或C(R5)(R6)组成的一组；R1选自可选择取代的芳基烷基和可选择取代的杂环芳基烷基；R2选自可选择取代的芳基或可选择取代的杂环芳基或NR7R8；R3、R4、R5、R6、R7和R8如本文所定义；n=0、1、2或3；o=0、1或2，但当o=0时，n为1、2或3，当o=1时，n为1或2。同时还提供了包含这些化合物的药物组合物。这些化合物在治疗各种疾病，包括心律失常方面具有用途。
• DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS
  申请人：Xention Limited

  公开号：EP2438055A1

  公开（公告）日：2012-04-11
• [EN] DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS<br/>[FR] DERIVES DE DIHYDROINDOLE ET DE TETRAHYDROISOQUINOLINE UTILES EN TANT QU'INHIBITEURS DES CANAUX POTASSIQUES
  申请人：XENTION LTD

  公开号：WO2010139967A1

  公开（公告）日：2010-12-09

  A compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein; A represents a chemical moiety with the general formula (II); X and Y are independently selected from a group consisting of CH2, CH(R5) or C(R5)(R6); R1 is selected from the group consisting of optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; R2 is selected from the group consisting of optionally substituted aryl or optionally substituted heteroaryl or NR7R8; R3 is selected from the group consisting of hydrogen, halogen, hydroxyl, alkoxy, aryloxy, optionally substituted alkyl, optionally substituted amino, optionally substituted amino sulfonyl or nitrile; R4 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted acyl, optionally substituted sulfonyl, optionally substituted sulfamoyl, optionally substituted aryl, optionally substituted arylalkyl, and optionally substituted heteroaryl; R5 and R6 for each occurrence is optionally substituted alkyl; R7 and R8 are the same or different and each represents hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted aryl or optionally substituted heteroaryl; n = 0, 1, 2 or 3; o = 0, 1 or 2 with the proviso that when o = 0, n is 1, 2 or 3 and when o = 1, n is 1 or 2 is provided. Pharmaceutical compositions comprising the compounds are also provided. These compounds are useful in the treatment of various disorders including arrhythmia.